Keywords: Gilead Sciences, Parmasset, Hepatitis C treatments

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

Article | 22 November 2011

Print This

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in